Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in HER3-Expressing Metastatic Breast Cancer
NCT02980341Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in breast cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants Reporting Treatment-emergent Adverse Events up to 9 months and Best Overall Tumor Response up to 9 months. Started Nov 2016; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02980341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980341.